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Keywords: GH, PRL, placenta, endometrial glands, placental lactogenThe placentas of ruminants and muroid rodents express prolactin (PRL)-related genes 
whereas the placentas of anthropoid primates express growth hormone (GH)-related 
genes. The evolution of placental expression is associated with acclerated evolution of 
the corresponding pituitary hormone and destabilization of conserved endocrine systems. 
In particular, placental hormones often evolve novel interactions with new receptors. The 
adaptive functions of some placental hormones may be revealed only under conditions of 
physiological stress.Introduction
Placental hormones are produced by offspring, but act on receptors of mothers. As 
such, placental hormones and maternal receptors are prime candidates for the expression 
of parent-offspring conflict [1,2]. The placenta is selected to secrete hormones into the 
mother’s circulation only if the hormones modify maternal physiology in ways that 
benefit the fetus, but maternal responses evolve to maximize maternal fitness. This paper 
will examine the actions of two ancient vertebrate hormones, and of placental versions of 
these hormones that have evolved independently in at least three groups of mammals.
Growth hormone (GH) and prolactin (PRL) are structurally-related molecules with 
structurally-related receptors (GHR and PRLR). GH and PRL exhibit highly divergent 
rates of molecular evolution in different mammalian lineages. In most mammals, these 
hormones are evolutionarily conservative, with a slow rate of amino acid substitutions. 
But, in at least three lineages — anthropoid primates, muroid rodents, and ruminants —
either GH, PRL, or both have undergone greatly accelerated evolutionary change. And, 
in all three lineages, GH-derived or PRL-derived genes are expressed in the placenta and 
signal via maternal GHRs or PRLRs. The accelerated evolution of GH and PRL in these 
lineages may reflect ongoing maternal-fetal conflict.
Growth hormone and prolactin
Growth hormone was so named because extracts from bovine pituitaries accelerated 
growth when administered to rats. But, the name may mislead as much as it informs: 
mammals continue to produce GH after they have reached adult size; exogenous GH 
suppresses rather than enhances growth in poultry [3]; and fasting elevates GH, but 
reduces growth, in teleost fishes [4]. In humans, basal GH is increased in kwashiorkor, 
marasmus, anorexia nervosa, and fasting. Growth and starvation are both situations in 
which a lipid-rich body would benefit from conserving amino acids rather than using 
them as substrates for gluconeogenesis. The primary function of GH may be to shift the 
body’s fuel preference from glucose to lipids [5].
Prolactin was so named because pituitary extracts induced lactation in mammals and 
production of ‘crop-milk’ in pigeons [6]. PRL also stimulates secretion of ‘uterine milk’ 
by the endometrium of rabbits and pigs [7,8], and PRLRs are present on endometrial 
glands of women, baboons, and sheep [9-11]. Decidual stromal cells of women and Old 
World monkeys produce PRL [10,12], but decidual PRL does not significantly enter 
the maternal or fetal circulation [13]. PRLRs are expressed on glandular epithelia and natural killer cells of the human decidua [9,14]. Therefore, a plausible hypothesis is that 
endometrial glands and decidual NK cells are the principal targets of PRL produced by 
the decidual stroma [15].
PRL is said to have more disparate actions than all other pituitary hormones 
combined [16]. Some patterns emerge, however. The promotion of parental behaviors 
[17,18], the elevation of PRL after coitus in rodents, rabbits, and humans [19-21], and 
the suppression of ovarian function and libido by hyperprolactinemia [22], all suggest 
that an ancient function of PRL may have been to shift the body’s priorities away 
from reproduction (in the narrow sense of mating and ovulation) toward other fitness-
enhancing activities.
Ligand/receptor interactions
PRL and GH signal by a process of sequential binding to two receptors. Each 
hormone has two receptor-binding sites. A molecule of unbound hormone initially binds 
via site 1 to the first receptor, forming a 1:1 complex. Only then is the hormone able to 
bind via site 2 to a second receptor, forming the active 1:2 complex. Unbound receptors 
can either bind to site 1 of a free hormone to form a 1:1 complex or to site 2 of a bound 
hormone to form a 1:2 complex. The likelihood of these different fates is determined by 
the relative abundance of free hormones and 1:1 complexes, and by the relative affinities 
of site 1 and site 2 for unbound receptors [23]. 
The process of sequential dimerization introduces complexities when interpreting 
whether a given hormone is acting as an agonist or an antagonist of GHRs or PRLRs, 
especially when multiple hormones compete for the same receptors. Each additional 
molecule of a hormone may facilitate or obstruct the formation of active 1:2 ligand-
receptor complexes depending on the frequency of unbound receptors. A hormone that, 
by itself, acts as a weak agonist may nevertheless antagonize the action of a second 
hormone with stronger agonist activity.
PRIMATES
Bushbaby GH differs from porcine GH by only four residues whereas human GH 
and porcine GH differ by 66 residues [24]. Thus, GH has changed little in the lineage 
leading to bushbabies but has undergone dramatic change in the lineage leading to 
humans since these lineages diverged from a common ancestor. Strepsirrhine primates, 
such as bushbabies, have a single evolutionarily conservative GH gene [24,25] whereas anthropoid primates, such as humans, have multiple GH-related genes that have 
undergone rapid evolutionary change [26].
Neither strepsirrhine nor anthropoid PRL loci have been duplicated, but these 
hormones exhibit a similar contrast in evolutionary rates to that observed for GH. 
Strepsirrhine PRLs are evolutionarily conservative whereas anthropoid PRLs have 
undergone a period of rapid evolution after the divergence of strepsirrhine and anthropoid 
primates, but before the separation of New World and Old World monkeys [27]. In 
parallel with its ligand, the PRLR has undergone accelerated evolution in anthropoid 
primates [28].
Growth hormones of humans, macaques, and squirrel monkeys bind to PRLRs as 
well as to GHRs, and are active in lactogenic (PRLR) as well as somatogenic (GHR) 
bioassays [29,30]. The lactogenic activity of anthropoid GHs implies that these hormones 
bind to two PRLRs via site 1 and site 2. An important evolutionary question is whether 
the initial mutation that conferred affinity for PRLR via site 1 was associated from the 
start with affinity for a second PRLR via site 2 or whether site-2 affinity was aquired 
subsequently. In the latter scenario, the initial mutation would have produced a GH that 
functioned as an antagonist of PRLRs by binding at site 1, but not at site 2.
Anthropoid primates possess a cluster of GH-related genes [31,32]. All genes of a 
cluster are, strictly speaking, orthologs of the single GH gene of other mammals. But, 
one gene is usually singled out as the ‘true’ GH, based on its expression in pituitary 
somatotrophs. The additional genes of apes and Old World monkeys are expressed in 
the placenta [32,33] but this has not been determined in New World monkeys. All GH-
like proteins of New World monkeys are more similar to each other than to any GH-like 
protein of apes or Old World monkeys, suggesting independent duplications of GH in the 
two lineages [34].
The growth hormone gene cluster of humans contains a single gene expressed in the 
anterior pituitary (GH1) plus four genes expressed in the placenta (CSHL1—CSH1—
GH2—CSH2). GH1 encodes human growth hormone (hGH), GH2 encodes human 
placental growth hormone (hPGH), and  CSH1 and CSH2 encode human placental 
lactogen (hPL) [32]. These hormones have different relative affinities for GHRs and 
PRLRs: hGH binds to both GHRs and PRLRs; hPL has high affinity for PRLRs but 
very weak affinity for GHRs [35]; and hPGH has high affinity for GHRs but negligible 
affinity for human PRLRs [36]. The simplest scenario is that the GH of an ancestral 
anthropoid primate bound promiscuously to GHRs and PRLRs. Promiscuous binding has 
been preserved by pituitary GH. In this scenario, hPL has evolved fidelity for PRLRs, 
and hPGH fidelity for GHRs, by a process of gene duplication and subfunctionalization. During human pregnancy, the placenta secretes a ligand of maternal GHRs (hPGH) 
and a ligand of maternal PRLRs (hPL). Concentrations of both ligands increase with 
advancing gestation. In the latter stages of pregnancy, the maternal pituitary has almost 
ceased producing hGH but produces hPRL at higher levels than in the nonpregnant state 
[37,38]. Maternal GH and PRL thus exhibit contrasting responses to pregnancy. As a 
result, maternal GHRs encounter only their placental ligand (hPGH) whereas maternal 
PRLRs encounter high levels of both maternal and placental ligands (hPRL and hPL). 
Concentrations of IGF-I and hPGH in maternal serum are tightly correlated in the 
second half of human pregnancy [39]. Therefore, hPGH acts as an agonist of maternal 
GHRs. The suppression of maternal pituitary hGH, as placental production of hPGH 
escalates, suggests that natural selection acting on mothers has favored reduced signaling 
via GHRs whereas natural selection acting on fetuses has favored increased signaling [2]. 
This hypothesis could explain why site 1 of hPL has lost its affinity for GHRs, because 
otherwise the colossal production of hPL near term would strongly antagonize fetally-
favored responses via maternal GHRs (by blocking receptor dimerization).
What benefits do human fetuses gain by activating maternal GHRs? As yet, no 
definitive answer can be given to this question, but some evolutionary hypotheses can be 
suggested. Among the known effects of hGH are increased lipolysis, increased hepatic 
output of glucose, and increased peripheral resistance to insulin. hPGH elicits similar 
effects in experimental systems [40,41]. Thus, hPGH may act in concert with other 
placental hormones to augment the supply of fatty acids and glucose to the placenta. 
Human mammary glands express both GHRs and PRLRs [42]. Thus, mammary GHRs 
are another possible target of hPGH.
PRLRs are expressed on glandular epithelia and uterine natural killer cells of the 
human decidua [9,14]. These PRLRs are targets for hPL produced by extravillous 
trophoblast [41] and hPRL produced by the decidual stroma [12]. Synctiotrophoblast 
is the source of hPL released into the general maternal circulation [44]. Many maternal 
tissues express PRLRs and are possible targets of circulating hPL.
The key question for understanding the function of hPL in pregnancy is whether hPL 
acts as an agonist or antagonist of PRLRs at the physiological concentrations of hPL and 
hPRL present during pregnancy. I have vacillated on this question. I initially proposed 
that the function of hPL was to activate maternal PRL receptors for fetal benefit [1]. At 
that time, I had not recognized the significance of elevated maternal hPRL, nor had I 
recognized the possibility that an abundant placental hormone could act as an antagonist 
of maternal receptors. If maternal PRL receptors do not discriminate between hPL and hPRL, the genetic-conflict hypothesis predicts that maternal production of hPRL should 
decrease in response to increasing placental production of hPL, contrary to observations. 
However, the hypothesis is compatible with elevated production of both hormones if one 
functions as an agonist and the other as an antagonist [2].
Ruminants
Both GH and PRL have undergone rapid evolution in the lineage leading to ruminants 
[26,45,46]. PRL is duplicated in all well-studied ruminants whereas most species have a 
single GH-like gene. Therefore, accelerated evolution of GH is observed in the absence 
of gene duplication. The cluster of PRL-like genes contains a gene expressed in the 
pituitary (PRL) and a ‘placental lactogen’ (PL), as well as prolactin-related proteins 
(PRPs) [47-49]. At least some, perhaps all, PRPs are expressed in the placenta. Ruminant 
PLs bind to both PRLRs and GHRs. They act as agonists of PRLRs but as antagonists of 
GHRs [50]. Ovine PL (oPL) can to bind to GHR via site 1 and PRLR via site 2 to form a 
GHR/PL/PRLR complex [51].
PRLRs are expressed on the glandular epithelia of ruminant endometria [11]. oPL 
binds to endometrial PRLRs and increases the secretion of ‘uterine milk’ into the uterine 
lumen [52-54]. Stimulation of uterolactation does not require PL to enter maternal blood. 
Thus, bovine PL is present at high concentrations in uterine fluids but is barely detectable 
in serum of pregnant cows [55,56]. Substantial quantities of oPL enter the circulation of 
pregnant ewes [57], raising the possibility that oPL targets PRLRs at extrauterine sites.
Rapid change of GH occurred in the period after ruminants diverged from their 
common ancestor with hippos and whales, but before chevrotains diverged from other 
ruminants [58,59]. The reason for the burst of adaptive change in GH is unknown but I 
conjecture that this is a consequence of the destabilization of ligand-receptor relations 
caused by PLs binding to GHRs. Domestic sheep and goats are polymorphic for a 
duplication of GH [60]. On haplotypes with two GH genes, one gene is expressed in the 
pituitary and the other in the placenta [61]. 
Muroid Rodents
Molecular evolution of GH is only modestly accelerated in muroid rodents whereas 
the evolution of PRL has been dramatically accelerated [45,46].  GH is represented by 
a single gene in rodent genomes but PRL has given rise to a large cluster of genes, most 
of which are expressed in the placenta. The PRL-related gene clusters of rats and mice each contain more than 20 genes, known by various names including placental lactogens 
(PLs), PRL-like proteins (PLPs), and proliferins (PLFs) [62].  Rodent PRL and PLs 
bind to PRLRs, whereas PLPs and PLFs bind to other, currently unidentified, receptors. 
This section will focus on ‘classical’ effects of PLs via maternal PRLRs before briefly 
discussing non-classical actions of PLPs and PLFs.
Muroid rodents have very short estrus cycles that are an adaptation for the rapid 
production of a new ‘clutch’ of eggs if mating fails. In the process, PRL has acquired 
a luteotrophic function that is perhaps unique to this group of mammals. Corpora lutea 
of unmated females are rapidly suppressed by activation of the progesterone-degrading 
enzyme 20a-hydroxysteroid dehydrogenase (20aHSD). PRL, and rodent PLs, bind to 
ovarian PRLRs and cause the inhibition of 20aHSD [63]. The source of luteotrophic 
PRL shifts during the course of a pregnancy. Coitus on the day of ovulation induces 
twice daily surges of PRL from a female’s anterior pituitary that maintain corpora lutea 
[19]. However, as pregnancy progresses, the luteotrophic effects of decidual PRL are 
supplemented by those of placental lactogens [64]. Rodent PLs may also confer benefits 
on offspring via PRLRs in other maternal tissues. Obvious candidates are actions on 
mammary glands [65] and the maternal brain [18]. 
Proliferin (PLF) and proliferin-related protein (PRP) bind to endothelial cells and 
have angiogenic and anti-angiogenic actions respectively. PLF is produced by the 
placenta in mid gestation and PRP in late gestation [66]. These molecules may function 
to increase and maintain maternal blood flow to the placenta [67]. Other things being 
equal, the recruitment of additional vessels to the implantation site will increase blood 
flow, whereas lengthening of existing vessels, or narrowing of their radius, will reduce 
flow.
Prolactin-like protein-A (PLP-A) is expressed in secondary trophoblast giant cells 
[68]. PLP-A binds to uterine natural killer cells in rats and inhibits the production of 
interferon g [69]. Plpa has been inactivated in mice with intriguing results. Under normal 
rearing conditions, homozygous null mothers with homozygous null litters successfully 
complete pregnancy. However, null litters aborted when null mothers were placed in 
hypobaric oxygen from day 7.5 of pregnancy whereas wild-type mothers, with wild-type 
litters, successfully completed pregnancy under the same conditions [70]. I conjecture 
that the physiological stress of hypoxia activates a facultative response of uterine natural 
killer cells to abort the pregnancy but this mechanism is blocked in wild-type mice by 
placentally-produced PLP-A. (In a similar vein, genetic deletions of hPL have little effect 
on the pregnancies of well-nourished women [71]. Perhaps, the crucial adaptive role of 
hPL will be revealed only in conditions of severe physiological stress.)In litter-producing species, evolutionary forces differ between placental hormones 
with paracrine effects at the maternal-fetal interface and placental hormones with 
endocrine effects at extrauterine sites. In the former case, the benefits of hormone 
production accrue directly to the producer whereas, in the latter case, the benefits are 
shared with other members of the litter. Production of a hormone with systemic maternal 
effects is a cooperative enterprise among the members of a litter. Offspring may be 
selected to skimp on their contribution to the ‘collective good’ because marginal benefits 
are shared but marginal costs are borne by each offspring individually [2]. 
Placental hormones and maternal-fetal conflict
Placental expression of GH- or PRL-related genes is correlated with accelerated 
evolution of GH and/or PRL. Accelerated evolution is not a mere side-effect of gene 
duplication because it is also observed for single-copy genes, such as the PRLs and 
PRLRs of anthropoid primates. Further comparative studies should provide greater 
resolution on the relative timing of accelerated evolution, gene duplications, placental 
expression, and changes in placental morphology.
Mother and fetus ‘disagree’ about the precise settings on homeostatic controls in 
the mother’s body. Placental hormone expression evolves to adjust these settings and 
maternal receptors and counter-hormones evolve to nudge the settings back toward 
the maternal optimum. If such a system reaches an evolutionary equilibirum, this state 
will be one in which both sides have taken all simple moves to adjust the controls in 
their favor. Such a state is likely to be unresponsive to fluctuations in the mother’s 
condition and not easily perturbed. These considerations may help to explain why 
placental hormones are produced in such large amounts and in amounts that vary little 
from moment to moment. On the time-scale of hours, even days, the release of placental 
hormones is constitutive rather than facultative.
Under optimal conditions, the divergence of interests between mother and fetus may 
be small; no more than a petty squabble over precisely how much glucose and lipid a 
fetus should receive, when both are in abundant supply. However, when the mother 
is physiologically threatened, maternal and fetal interests can diverge markedly. For 
instance, mother and fetus may differ in the amount of ‘collateral damage’ to trophoblast 
each is prepared to countenance in the course of combating an intrauterine infection. 
From the evolutionary perspective of the fetus, this is an existential threat but, from the 
evolutionary perspective of mothers, aborted offspring are partially replaceable when 
conditions improve. The absence of a placental hormone may have little noticeable effect when maternal 
and fetal interests are similar, because a mother’s body will readily adjust homeostatic 
controls to meet her interests and these interests will include the delivery of a healthy 
offspring. But, when maternal and fetal interests diverge, placental hormones may 
become critical for offspring survival, but at the expense of mothers’ expectations of 
future reproduction. References
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